Danaher Corporation (DHR)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$194.18+0.29%
Close 2026-07-07 · 1-day change
Reading DHR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DHR free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading DHR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DHR free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on steady revenue growth and earnings per share (EPS) increases. The current thesis state is intact, supported by strong recent financial performance and a positive sector backdrop.
The market currently prices DHR as relatively cheap compared to its peers, with a low expectations gap. This suggests that investors may not be fully accounting for the potential upside from its recent performance and sector improvements.
Management aims to grow core revenue by 3% to 6%, but recent results show limited progress towards the upper end of this target. However, EPS guidance is on track, with recent increases indicating strong earnings momentum.
The long-term thesis hinges on the performance of sector bellwethers like TMO, IDXX, and NTRA. If these companies continue to beat earnings and guide higher, it could provide a favorable environment for DHR. Conversely, any negative guidance from these peers could pose risks to DHR's performance.
Overall, DHR's fundamentals and sector context suggest a stable outlook over the next 1 to 3 years. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read, indicating strong recent performance. However, growth expectations have been challenged as the company fell short of its core revenue growth target of 3% to 6%.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This report will provide insights into revenue and profit trends. It is a key event for investors.
Confirms one read:Earnings report shows better than expected revenue and EPS.
Confirms the other:Earnings report shows worse than expected revenue and EPS.
Why it matters: This will show if Danaher is on track to meet its full-year growth target of 3% to 6%.
Confirms:Q2 non-GAAP core revenue growth reported at 3% or higher year-over-year.
Disproves:Q2 non-GAAP core revenue growth was below 2% compared to last year.
Why it matters: This will show if Danaher is keeping its growth and confidence in earnings.
Confirms:Guidance for adjusted diluted net earnings per share is raised above $8.50.
Disproves:Guidance for adjusted diluted net earnings per share is now below $8.35.
Why it matters: A buyback shows management's confidence in the company's value. It may help shareholders.
Confirms:Danaher announces a new share buyback program during Q2 2026.
Disproves:No announcement of a share buyback program in Q2 2026.
Why it matters: Details on the buyback may show management's trust in the company's value.
Confirms:Announcement of specific terms or amounts for the share buyback program.
Disproves:No further details or a cancellation of the buyback program.
Why it matters: A good buyback program can support the stock price. It shows management's confidence. Poor execution may cause negative feelings.
Confirms one read:The stock price goes up after the buyback program is announced.
Confirms the other:Stock price declines or remains flat despite the buyback announcement.
Why it matters: Higher EPS guidance means stronger profit expectations. This can help investor confidence.
Confirms:Management raises EPS guidance for the next quarters.
Disproves:EPS guidance remains unchanged or is lowered.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The acquisition could improve Danaher's diagnostics segment. This may help future growth. Delays or problems could hurt investor confidence.
Confirms:The acquisition of Masimo is on track. All regulatory approvals are in place.
Disproves:The acquisition may face delays. It might not get the needed regulatory approvals.